CARVYKTI® is the first and only cell therapy to significantly …
Sep 27, 2024 · CARTITUDE-4 (NCT04181827) is the first randomized Phase 3 study evaluating the efficacy and safety of CARVYKTI ®. The study compares CARVYKTI ® with standard of care treatments PVd or DPd...
FDA Approves Carvykti CAR T-Cell Therapy for Multiple Myeloma
Mar 30, 2022 · On February 28, the Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for adults with multiple myeloma that is not responding to treatment (refractory) or has returned after treatment (relapsed).
CARVYKTI® is the first and only cell therapy to significantly …
Sep 27, 2024 · CARTITUDE-4 (NCT04181827) is the first randomized Phase 3 study evaluating the efficacy and safety of CARVYKTI ®. The study compares CARVYKTI ® with standard of care treatments PVd or DPd in adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy.
CARVYKTI® is the First and Only Cell Therapy to - GlobeNewswire
Sep 27, 2024 · Landmark CARTITUDE-4 study results show CARVYKTI® reduced the risk of death by 45 percent after three-year follow-up. Late-breaking data featured in an oral presentation at the 21st...
J&J, Legend's Carvykti quickly leaps ahead of BMS' rival CAR-T
Apr 8, 2024 · With an approval Friday, Carvykti has become the first BCMA-directed therapy for multiple myeloma patients who have received at least just one prior line of therapy. To be eligible, a patient’s...
Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted …
Dec 12, 2023 · CARVYKTI ® is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient's own T-cells with a transgene encoding chimeric antigen receptor (CAR)...
Carvykti, Abecma move earlier in multiple myeloma treatment
Nov 7, 2024 · Carvykti (ciltacabtagene autoleucel) can now be used after first relapse in patients who have been previously treated with a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and...
J&J, Legend solidify Carvykti's lead in earlier multiple myeloma …
Sep 30, 2024 · After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’s Carvykti has once again mounted a...
Trial sets up earlier use of J&J's Carvykti in myeloma
Nov 8, 2024 · BCMA-directed cell therapy Carvykti (ciltacabtagene autoleucel) has seen sluggish growth since it was first approved by the FDA in March 2022 as a fifth-line or later therapy for multiple...
Carvykti Effective for R/R Multiple Myeloma in Real-World Setting
Nov 5, 2024 · Treatment with Carvykti (ciltacabtagene autoleucel, also known as cilta-cel), has been shown to be effective among patients with relapsed or refractory multiple myeloma in a real-world setting, meaning in treating patients outside of a clinical trial.